Astrazeneca ADR Stock
-
Your prediction
Astrazeneca ADR Stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
Cons
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | - | - | - | - | - | - | - |
| GSK plc ADR | -0.920% | -4.072% | -15.200% | 28.485% | 1.435% | 26.946% | 7.342% |
| Bayer AG ADR | -2.480% | 1.105% | -7.576% | 56.410% | 3.977% | -31.203% | -35.106% |
| Roche Holding AG ADR | 0.430% | 0.249% | 2.209% | 22.859% | -0.545% | 18.771% | 27.740% |
News
Innate Pharma Q1 Earnings Call Highlights
Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate
AstraZeneca and OMP Demonstrate Planning at the Speed of Change at Gartner Supply Chain Symposium/Xpo(TM) 2026
How decision velocity closes the gap between insight and action in complex, fast-moving supply chains
ANTWERPEN, BE / ACCESS Newswire / May 7, 2026 / OMP, a leader in AI-powered supply
P&G and OMP Showcase the Path to Autonomous, Decision-Centric Planning at Gartner Supply Chain Symposium/Xpo 2026
How decision velocity is closing the gap between insight and action across one of the world's most complex value chains
ATLANTA, GA / ACCESS Newswire / April 14, 2026 / OMP, a leader in

